spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Arcis Biotechnology and Mirnax Biosens sign exclusive license agreement for Arcis sample prep technology

Arcis Biotechnology

Enables stabilisation of microRNA biomarkers for early disease diagnosis

Daresbury, UK, and Madrid, Spain, 16 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, and Mirnax Biosens (“Mirnax”), the developer of microRNA (miRNA) biomarkers for clinical diagnostics, today announced they have signed an exclusive license agreement for use of Arcis sample preparation and preservation technology.

Under the terms of the agreement, Mirnax gains access to Arcis’ nucleic acid sample preparation and preservation technology, to improve the stability of its clinically validated miRNA biomarkers for early disease detection. Arcis will also work with Mirnax to develop a microfluidic device integrating both technologies.

Mirnax’ biomarkers are designed for early disease diagnosis, including cancer, arthritis, and kidney disease. However, miRNA is often difficult to preserve, degrading rapidly following extraction, which will affect the accuracy of diagnosis. Arcis’ two-step, rapid nucleic acid extraction and preservation technology enables the fragile miRNA biomarkers to be extracted and stabilised in less than three minutes, without the need for instrumentation or heating or cooling steps.

Dr Jan Rogers, Chief Scientific Officer, Arcis Biotechnology, commented:“We are excited to partner with Mirnax, combining our synergistic technologies to improve the accuracy and speed of disease diagnoses. This latest agreement demonstrates the wide breadth of applications for our nucleic acid sample preparation technology, including clinical diagnostics which is an area that we look forward to exploring further.”

Enrique Sainz Martinez, Chief Executive Officer, Mirnax Biosens, said: “Using the Arcis sample prep technology we are able to successfully generate stable biomarkers for the diagnosis of pathologies with high incidence in the current population. This agreement supports our mission to develop products with high clinical value, and to ultimately improve patient quality of life.”
phone 01925 607100
email info@arcisbio.com
web www.arcisbio.com
email Arcis Biotechnology Limited, The Innovation Centre, Sci-tech Daresbury, Keckwick Lane, Daresbury, Cheshire, WA4 4FS, UK
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Biopharmaceuticals company attends sector conferences in the online format

A leading Contract Development and Manufacturing Organization (CDMO), 3P Biopharmaceuticals, specialized in process development and cGMP manufacturing of biologics, is attending the most relevant events of the sector, although in digital format, as a consequence of the cancellation of global events due to the pandemic. COVID19 has affected everyone and all sectors.
More info >>


White Papers

Clinical Research in Spain

BioClever

This whitepaper is on clinical research in Spain, giving a general outline of the main characteristics of research in this country and an overview of the applicable regulations, along with the reasons why Spain is a good place to do research.
More info >>

Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement